Fractyl Health, Inc. (GUTS)
Nasdaq · Healthcare · Biotechnology
$4.56−6.54%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $726M
- 52-week range
- $0.377 – $4.81
- 52-week change
- −72.31%
- EPS (trailing)
- −$10.56
- Analyst rating
- 1.3 Strong buy
- Next earnings
- Nov 11, 2026
Fiscal year to Dec 2025
- Revenue
- $0K (−100.00%)
- Net income
- −$141M
- Diluted EPS
- −$1.86
- Free cash flow
- −$90.9M
From the company’s annual report on SEC EDGAR.
About Fractyl Health, Inc.
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.
Headquarters: Burlington, United States · 100 employees · fractyl.com